Do analysts prefer SCPS or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, SCPS or ADTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Aditxt N/A N/A -$41.71M -$100.79 thousand N/A

Does the media refer more to SCPS or ADTX?

In the previous week, Aditxt had 7 more articles in the media than Scopus BioPharma. MarketBeat recorded 8 mentions for Aditxt and 1 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 0.72 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scopus BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aditxt 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, VINC or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is VINC or SCPS more profitable?

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Vincerx Pharma N/A -248.33% -132.73% Scopus BioPharma N/A N/A N/A

Which has better valuation and earnings, VAXX or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxxinity N/A N/A -$56.93M -$0.45 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is VAXX or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Vaxxinity N/A N/A N/A Scopus BioPharma N/A N/A N/A

Which has preferable valuation and earnings, SCPS or ARDS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 0.00

Is SCPS or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Which has higher earnings and valuation, TRVN or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Trevena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevena $443K 0.00 -$40.29M -$47.04 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is TRVN or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Scopus BioPharma N/A N/A N/A

Scopus BioPharma (SCPS) Competitors

$0.0004 0.00 (0.00%)

As of 06/12/2026 10:38 AM Eastern

Compare

SCPS vs. ADTX, VINC, VAXX, ARDS, and TRVN

Should you buy Scopus BioPharma stock or one of its competitors? MarketBeat compares Scopus BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scopus BioPharma include Aditxt (ADTX), Vincerx Pharma (VINC), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Aditxt?

Scopus BioPharma (NASDAQ:SCPS) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, Aditxt had 7 more articles in the media than Scopus BioPharma. MarketBeat recorded 8 mentions for Aditxt and 1 mentions for Scopus BioPharma. Aditxt's average media sentiment score of 0.72 beat Scopus BioPharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scopus BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aditxt	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Aditxt has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aditxt	N/A	N/A	-$41.71M	-$100.79 thousand	N/A

15.5% of Aditxt shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scopus BioPharma and Aditxt tied by winning 5 of the 10 factors compared between the two stocks.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Scopus BioPharma had 1 more articles in the media than Vincerx Pharma. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Vincerx Pharma	Neutral
Scopus BioPharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vincerx Pharma has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Summary

Scopus BioPharma beats Vincerx Pharma on 4 of the 7 factors compared between the two stocks.

How does Scopus BioPharma compare to Vaxxinity?

Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

82.9% of Vaxxinity shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxxinity	N/A	N/A	-$56.93M	-$0.45	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vaxxinity	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Scopus BioPharma had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Vaxxinity	Neutral
Scopus BioPharma	Neutral

Vaxxinity has a beta of -79.33, indicating that its share price is 8,033% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Summary

Scopus BioPharma beats Vaxxinity on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Scopus BioPharma had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Aridis Pharmaceuticals. Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Aridis Pharmaceuticals	Neutral

Scopus BioPharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its stock price is 4,397% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	0.00

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Scopus BioPharma had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Scopus BioPharma	Neutral

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Trevena has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market.

Summary

Scopus BioPharma beats Trevena on 4 of the 7 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCPS vs. The Competition

Export

Metric	Scopus BioPharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17K	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	N/A	1.45	24.00	24.42
Price / Sales	N/A	120.49	515.84	118.72
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	7.85	10.60	6.82
Net Income	-$11.61M	-$4.88M	$3.57B	$337.56M
7 Day Performance	N/A	0.64%	0.59%	1.16%
1 Month Performance	N/A	-0.16%	1.54%	3.16%
1 Year Performance	N/A	47.51%	25.41%	30.60%

Scopus BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+33.3%	$17K	N/A	N/A	9	Gap Up
ADTX Aditxt	1.0226 of 5 stars	$0.08 -18.9%	N/A	-100.0%	$77K	$14.34K	N/A	60	Gap Down High Trading Volume
VINC Vincerx Pharma	N/A	$0.01 -3.9%	N/A	-76.2%	$64K	N/A	N/A	60	Gap Down
VAXX Vaxxinity	N/A	$0.00 +100.0%	N/A	+0.0%	$25K	N/A	N/A	90	Gap Up High Trading Volume
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+100.0%	$11K	N/A	0.00	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scopus BioPharma (SCPS) Competitors

SCPS vs. ADTX, VINC, VAXX, ARDS, and TRVN

How does Scopus BioPharma compare to Aditxt?

Summary

How does Scopus BioPharma compare to Vincerx Pharma?

Summary

How does Scopus BioPharma compare to Vaxxinity?

Summary

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Summary

How does Scopus BioPharma compare to Trevena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scopus BioPharma (SCPS) Competitors

SCPS vs. ADTX, VINC, VAXX, ARDS, and TRVN

How does Scopus BioPharma compare to Aditxt?

Does the media refer more to SCPS or ADTX?

Which has more risk and volatility, SCPS or ADTX?

Which has higher valuation and earnings, SCPS or ADTX?

Do insiders and institutionals hold more shares of SCPS or ADTX?

Is SCPS or ADTX more profitable?

Do analysts prefer SCPS or ADTX?

Summary

How does Scopus BioPharma compare to Vincerx Pharma?

Is VINC or SCPS more profitable?

Does the media prefer VINC or SCPS?

Which has stronger valuation and earnings, VINC or SCPS?

Do institutionals & insiders believe in VINC or SCPS?

Which has more volatility and risk, VINC or SCPS?

Summary

How does Scopus BioPharma compare to Vaxxinity?

Do insiders and institutionals have more ownership in VAXX or SCPS?

Which has better valuation and earnings, VAXX or SCPS?

Is VAXX or SCPS more profitable?

Does the media favor VAXX or SCPS?

Which has more risk and volatility, VAXX or SCPS?

Summary

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Is SCPS or ARDS more profitable?

Do insiders and institutionals hold more shares of SCPS or ARDS?

Does the media prefer SCPS or ARDS?

Which has more risk & volatility, SCPS or ARDS?

Which has preferable valuation and earnings, SCPS or ARDS?

Summary

How does Scopus BioPharma compare to Trevena?

Is TRVN or SCPS more profitable?

Does the media favor TRVN or SCPS?

Which has higher earnings and valuation, TRVN or SCPS?

Do institutionals & insiders have more ownership in TRVN or SCPS?

Which has more volatility & risk, TRVN or SCPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPS vs. The Competition

Scopus BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools